a clinical stage biopharmaceutical company, which engages in the research and development of oncology therapeutics
Industry Biotechnology
A.I.dvisor tells us that IRD and VYGR have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that IRD and VYGR's prices will move in lockstep.
Ticker / NAME | Correlation To IRD | 1D Price Change % | ||
---|---|---|---|---|
IRD | 100% | -8.84% | ||
VYGR - IRD | 32% Poorly correlated | -3.55% | ||
NTLA - IRD | 32% Poorly correlated | -1.87% | ||
VRNA - IRD | 32% Poorly correlated | -2.39% | ||
BGNE - IRD | 31% Poorly correlated | +1.55% | ||
CTMX - IRD | 30% Poorly correlated | -1.74% | ||
More |